Tetraneuron

tetraneuron.com ↗ ·Madrid ·Series A

Tetraneuron is a Madrid-based clinical-stage biotech developing AAV-based gene therapies for neurodegenerative diseases, spun out of the Cajal Institute (CSIC). Its platform is built on E2F4DN, a dominant-negative form of the transcription factor E2F4 that aims to restore neuronal homeostasis and halt disease progression; lead candidate TET-101 targets Alzheimer's disease. In December 2025 it raised roughly €5M led by German fund GIMIC Ventures plus family offices, to file a Clinical Trial Application in Europe.

Founded

2012

Founders

Total funds raised

€12.4M

SectorsBiotech, Gene Therapy, Neuroscience, Pharma Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

José M. Frade

Co-Founder & Chief Scientific Officer

Manuel Nuñez González

Chairman & Co-Founder

Global models 5

AskBio

United States · www.askbio.com ↗

Clinical-stage AAV gene therapy developer with a neurodegenerative pipeline (Parkinson's, MSA) that was acquired by Bayer, the exit path a CNS gene-therapy asset developer like Tetraneuron would aim for.

$235MComparable

Passage Bio

United States · www.passagebio.com ↗

VC-backed clinical-stage AAV gene therapy company targeting neurodegenerative diseases such as frontotemporal dementia, taking its own candidates from academic biology into clinical trials.

$225MComparable

Prevail Therapeutics

United States · www.prevailtherapeutics.com ↗

AAV gene therapies for neurodegeneration (Parkinson's, FTD), built on academic science and taken to the clinic before Eli Lilly bought it, the same asset-to-exit model.

$204MComparable

Lexeo Therapeutics

United States · www.lexeotx.com ↗

Clinical-stage AAV gene therapy company whose lead programmes include an APOE4-targeted Alzheimer's therapy, directly overlapping TET-101's indication and approach.

$185MComparable

Capsida Biotherapeutics

United States · capsida.com ↗

Venture-backed AAV gene therapy company for brain diseases, advancing its own CNS candidates and partnering with pharma (AbbVie, Lilly).

$140MComparable

In the same niche 67 others

See all in the Start-ups Map →

Highlight Therapeutics

+61 more →

Notes: Most funded first

Investors 3

Open as list →

GIMIC Ventures

Series A 2025 Germany

Johnson & Johnson Innovation (JLABS)

jnjinnovation.com ↗

Investor United States

Funding rounds 3

Date	Round	Amount	Lead
2025-12-09	Series A (estimated)	€4.9M	Lead not disclosed +1 more
2022-12-27	Series A (estimated)	€5M	Lead not disclosed
2021-06-19	Seed (estimated)	approximately €2.5M	Lead not disclosed

News

No coverage on record yet.